問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Orthopedics

Division of General Surgery

Division of Hematology & Oncology

National Taiwan University Cancer Center (在職)

Division of Orthopedics

Division of Hematology & Oncology

更新時間：2023-09-19

楊士弘YANG, SHIH-HUNG
  • Principal Investigator
  • Clinical Trial Experience (year) 12 years 9 個月

Recruiting Trial

30Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

楊士弘

List

62Cases

2012-05-15 - 2020-09-08

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2013-09-01 - 2017-05-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2012-05-23 - 2015-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2019-04-15 - 2021-10-31

Phase II

A phase II study of S-1 Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer in Taiwan

  • Condition/Disease

    Resected Pancreatic Cancer

  • Test Drug

    TS-1® (S-1)

Participate Sites
4Sites

Recruiting4Sites

2014-11-01 - 2016-10-31

Phase II

A study of S-1 in combination with gemcitabine as first-line treatment in patients with advanced biliary tract cancer

  • Condition/Disease

    advanced biliary tract cancer

  • Test Drug

    TS-1®

Participate Sites
4Sites

Terminated4Sites

2014-09-15 - 2016-12-31

Phase III

A Double-blind, Randomised, Placebo Controlled Phase III Study of Nintedanib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Therapies.

  • Condition/Disease

    Colorectal cancer

  • Test Drug

    Nintedanib (BIBF 1120)

Participate Sites
5Sites

Terminated5Sites

2012-10-01 - 2015-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2018-10-01 - 2021-08-31

Phase II

A Phase 2 Study of Cabiralizumab (BMS-986227, FPA008) Administered in Combination With Nivolumab (BMS-936558) With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer

  • Condition/Disease

    Advanced Pancreatic Cancer

  • Test Drug

    Cabiralizumab (BMS-986227, FPA008)

Participate Sites
2Sites

Terminated2Sites

李重賓
Taipei Veterans General Hospital

Digestive System Department

2023-07-01 - 2026-07-01

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2019-03-01 - 2021-12-31

Phase I

A Phase I Dose Escalation Study, With Cohort Expansion, to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AbGn-107 Therapy in Patients With Chemo-refractory Locally Advanced, Recurrent, or Metastatic Gastric, Colorectal, Pancreatic or Biliary Cancer

  • Condition/Disease

    Gastric, Colorectal, Pancreatic or Biliary Cancer

  • Test Drug

    AbGn-107

Participate Sites
3Sites

Terminated3Sites

1 3 4 5 6 7
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB